izpis_h1_title_alt

Cannabinoids and hormone receptor-positive breast cancer treatment
ID Dobovišek, Luka (Author), ID Krstanović, Fran (Author), ID Borštnar, Simona (Author), ID Debeljak, Nataša (Author)

.pdfPDF - Presentation file, Download (1,53 MB)
MD5: 26555D7A0CFCD0CAFC2AED2FCF7A90C8
URLURL - Source URL, Visit https://www.mdpi.com/2072-6694/12/3/525 This link opens in a new window

Abstract
Breast cancer (BC) is the most common cancer in women worldwide. Approximately 70–80% of BCs express estrogen receptors (ER), which predict the response to endocrine therapy (ET), and are therefore hormone receptor-positive (HR+). Endogenous cannabinoids together with cannabinoid receptor 1 and 2 (CB1, CB2) constitute the basis of the endocannabinoid system. Interactions of cannabinoids with hypothalamic–pituitary–gonadal axis hormones are well documented, and two studies found a positive correlation between peak plasma endogenous cannabinoid anandamide with peak plasma 17β-estradiol, luteinizing hormone and folliclestimulating hormone levels at ovulation in healthy premenopausal women. Do cannabinoids have an effect on HR+ BC? In this paper we review known and possible interactions between cannabinoids and specific HR+ BC treatments. In preclinical studies, CB1 and CB2 agonists (i.e., anandamide, THC) have been shown to inhibit the proliferation of ER positive BC cell lines. There is less evidence for antitumor cannabinoid action in HR+ BC in animal models and there are no clinical trials exploring the effects of cannabinoids on HR+ BC treatment outcomes. Two studies have shown that tamoxifen and several other selective estrogen receptor modulators (SERM) can act as inverse agonists on CB1 and CB2, an interaction with possible clinical consequences. In addition, cannabinoid action could interact with other commonly used endocrine and targeted therapies used in the treatment of HR+ BC.

Language:English
Keywords:hormone receptor, breast cancer, cannabinoids, treatment, CBD, THC, estrogen, cannabinoid receptor
Work type:Article
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2020
Number of pages:12 str.
Numbering:Vol. 12, iss. 3, art. 525
PID:20.500.12556/RUL-133624 This link opens in a new window
UDC:616-006
ISSN on article:2072-6694
DOI:10.3390/cancers12030525 This link opens in a new window
COBISS.SI-ID:34716889 This link opens in a new window
Publication date in RUL:06.12.2021
Views:648
Downloads:182
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Cancers
Shortened title:Cancers
Publisher:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.03.2020

Secondary language

Language:Slovenian
Keywords:hormonski receptor, rak dojke, kanabinoidi

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0390
Name:Funkcijska genomika in biotehnologija za zdravje

Funder:ARRS - Slovenian Research Agency
Project number:P3-0321
Name:Napovedni dejavniki poteka bolezni in odgovora na zdravljenje pri različnih vrstah raka

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back